Table 1.

Clinical characteristics by patient subgroups

	Long-PFS		Multiple Responders^d		Long-Term Survivors^e		Control^f
	(n = 73)		(n = 21)		(n = 43)		(n = 710)
Characteristics	n (%)	P	n (%)	P	n (%)	P	n (%)
Age at diagnosis, y
Median	59	0.30^a	56	0.04^a	59	0.58^a	62
Range	29–77		39–75		40–77		24–80
Primary site
Ovary	58 (79)	0.01^b	14 (67)	0.17^b	31 (72)	0.05^b	537 (76)
Peritoneum	9 (12)		5 (24)		8 (19)		154 (22)
Fallopian tube	6 (8)		2 (10)		4 (9)		19 (3)
FIGO stage
IIIC	62 (85)	0.80^b	18 (86)	0.81^b	34 (79)	0.42^b	595 (84)
IV	11 (15)		3 (14)		9 (21)		115 (16)
Residual disease^g
Nil	0 (0)	<0.001^b	2 (10)	0.03^b	0 (0)	0.006^b	146 (21)
≤1 cm	35 (48)		14 (67)		18 (42)		222 (31)
>1 cm	24 (33)		4 (19)		15 (35)		197 (28)
Size unknown	12 (16)		1 (5)		9 (21)		86 (12)
Not resected	2 (3)		0 (0)		1 (2)		15 (2)
Not known	0 (0)		0 (0)		0 (0)		44 (6)
Neoadjuvant therapy
Yes	1 (1)	<0.001^b	3 (14)	0.66^b	0 (0)	0.002^b	128 (18)
No	72 (99)		18 (86)		43 (100)		582^k (82)
Primary platinum therapy
Yes	73 (100)	0.16^b	21 (100)	0.45^b	43 (100)	0.28^b	691^k (97)
No	0 (0)		0 (0)		0 (0)		19 (3)
Primary treatment details^h
Platinum/taxane	61 (84)	0.06^b	18 (86)	0.35^b	34 (79)	0.35^b	561 (79)
Platinum only	4 (5)		0 (0)		3 (7)		74 (10)
Platinum/taxane/otherⁱ	4 (5)		2 (10)		4 (9)		45 (6)
Platinum/other^j	4 (5)		1 (5)		2 (5)		11^k (2)
No treatment	0 (0)		0 (0)		0 (0)		19 (3)
Current status
Alive with no progression	41 (56)	<0.001^b	0 (0)	0.44^b	29 (67)	<0.001^b	28 (4)
Alive with progression	8 (11)		0 (0)		7 (16)		24 (3)
Dead	24 (33)		21 (100)		7 (16)		658 (93)
Progression-free survival from diagnosis (months)
Median	161.9	<0.001^c	18.2	0.32^c	Undefined	<0.001^c	11.9
Range	36.7–247.5		9.60–37.0		15.6–247.5		0–149.8
Overall survival from diagnosis (months)
Median	Undefined	<0.001^c	70.2	0.004^c	Undefined	<0.001^c	33.1
Range	36.7–247.5		43.2–122.8		120.8–247.5		0–268.6
>10 years overall survival from diagnosis	40 (55)		1 (5)		43 (100)		33 (5)
Overall grade
1	0 (0)	0.10^b	0 (0)	0.56^b	0 (0)	0.08^b	33 (6)
2	13 (19)		4 (22)		13 (31)		109 (20)
3	57 (81)		14 (78)		29 (69)		416 (75)
Not known/neoadjuvant^l	3		3		1		152

NOTE: Exceptional Responder patient subgroups were compared with unselected patients with advanced stage (stage IIIC/IV) serous ovarian cancer (control). Statistical comparisons were calculated as follows:
↵^aMann–Whitney test.
↵^bχ² test.
↵^cLog-rank test.
↵^dIncludes one case that meets the criteria for Long-PFS, Multiple Responder and Long-Term Survivor.
↵^eIncludes 40 cases that meet the criteria for Long-PFS and Long-Term Survivor.
↵^fUnselected serous ovarian cancer cohort excluding cases that meet criteria for Long-PFS, Multiple Responder or Long-Term Survivor (n = 75).
↵^gPatients who had residual disease after primary cytoreductive surgery but the size was not recorded were classified as “Size unknown,” and patients for whom it was not recorded whether or not they had residual disease were classified as “Not known.”
↵^hIntraperitoneal chemotherapy received (number of patients indicated in brackets): Long-PFS (1), Multiple Responder (1), Control (6).
↵ⁱOther chemotherapy received in addition to platinum/taxane: Long-PFS: gemcitabine (3), topetecan (1): Multiple Responder: gemcitabine (1), liposomal doxorubicin (1); Long-Term Survivor: gemcitabine (3), topetecan (1); Control: gemcitabine (18), liposomal doxorubicin (18), topetecan (6), bevacizumab (1), etoposide (1), and doxorubicin (1).
↵^jOther chemotherapy received in addition to platinum: Long-PFS: gemcitabine (2), cyclophosphamide (1), not known (1): Multiple Responder: cyclophosphamide (1); Long-Term Survivor: cyclophosphamide (1), not known (1). Control: gemcitabine (4), topotecan (3), cyclophosphamide (1), not known (3).
↵^kIncludes 3 patients where primary chemotherapy details are not known.
↵^lPatients who received neoadjuvant chemotherapy or for whom grade was not known were excluded from overall grade analysis.